Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that the Company has appointed Kevin Lorenz as their U.S. Head of Commercial Development, effective immediately. Mr. Lorenz will lead Awakn's therapeutics commercialization activities in the United States, starting with the launch of its Licensing Partnership business which is scheduled and expected to generate revenue for the second half of 2022.

Mr. Lorenz brings deep commercial biotech experience to Awakn, having spent two decades in the pharmaceutical sales industry, particularly in the U.S. addiction treatment market. Previously, he worked at Alkermes as Senior Regional Sales Director, where he directed a team of leaders and their representatives covering 32 states for Vivitrol, an FDA-approved medication for the treatment of Alcohol Use Disorder and Opiate Use Disorder. During his time with Alkermes, Mr. Lorenz was responsible for half of the U.S. sales of Vivitrol, which was worth $170m per annum. Before Alkermes, Mr. Lorenz worked at Cephalon Inc. and Janssen pharmaceuticals amongst others. He received his degree from Lambuth University.

Anthony Tennyson, Chief Executive Officer of Awakn commented "We are delighted to have someone of Kevin's calibre, who is an industry leader in his field, join our organization. Having the right person with the right network to launch and scale a part of our business that has immense potential was a critical decision. The addiction treatment and rehabilitation industry in the U.S. alone is worth almost $40 billion per annum, and this is with treatments that simply are not as effective as ours. We will translate our hugely positive clinical trial results into real change in so many people lives who are currently suffering from AUD. We believe our offering is going to disrupt the U.S. addiction treatment industry."

In the US, the drug and alcohol addictions treatment industry, while being a multi-billion-dollar industry, has very high failure rates and penetration rates are very low¹. Awakn plans to partner with existing addiction treatment clinic operators to enable them to provide evidence backed effective ketamine-assisted therapy treatments for Alcohol Use Disorder based on research from Awakn's recently published Phase II a/b clinical trial². The ground-breaking results of the trial showed 86% abstinence at 6 months post treatment, which is more effective than any treatments currently available in the alcohol addiction market. In addition to this, it showed a 2.7 times reduction in the chance of relapse in comparison to the placebo group, a statistically significant increase in liver function across several markers and a statistically significant reduction in depression.

Kevin Lorenz, Awakn's U.S. Head of Commercialization, stated "I am excited and proud to join the Awakn team. The debilitating effects Alcohol Use Disorder can have on patients and their families are well known and well documented. Perhaps less well known are the tremendous positive benefits experienced by patients, families and communities when those in treatment achieve and maintain Recovery. Millions of people in the US struggling with AUD need more effective treatment options, and Awakn is bringing innovation and new tools into this space. As a member of the Awakn team, I am excited to help make these options known and accessible to providers and their patients."

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction. Awakn's team consists of renowned research experts and world leading chemists, scientists, psychiatrists, and psychologists. Addiction is one of the biggest unmet medical needs of our time, affecting over 20% of the global population and is an industry valued at over $100bn per annum. Awakn is disrupting this underperforming industry by rapidly advancing the next generation of psychedelic drugs and therapies to be used in combination, through preclinical research and clinical stage trials.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Notice Regarding Forward-Looking Information

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's and Awakn's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
This email address is being protected from spambots. You need JavaScript enabled to view it.

Rest of World: ROAD Communications
Paul Jarman / Nora Popova
This email address is being protected from spambots. You need JavaScript enabled to view it.